Histopathology analysis confirmed improved 5-year survival in Multikine-treated subjects, showed improved progression free survival and improved local regional control, and significantly lowered death ...

Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non–Small-Cell Lung Cancer A single-institutional ...

Surgical resection is sufficient for low-risk pediatric NRSTS, with high survival rates observed without adjuvant treatment. The study utilized data from CWS-96 and CWS-2002P trials, focusing on ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were ...